Hematological oncologyHumansHodgkin DiseaseBrentuximab VedotinCost-Benefit AnalysisNivolumab
International Cost-Effectiveness Analysis of Nivolumab Versus Brentuximab Vedotin for Patients With Advanced-Stage Classic Hodgkin's Lymphoma.
Youwen Zhu, Kun Liu, Steven T Rosen, Hong Zhu, Wei Liu
Published: 202610.1002/hon.70165
Abstract
Programmed death-1 (PD-1) blockade offers a survival advantage over antibody-drug conjugate (ADC) treatment in classic Hodgkin lymphoma (cHL). As such, an updated pharmacoeconomic analysis of these different therapeutic strategies is indicated. This…
Preview only. Read the full abstract at the source